ArticleJournal of the National Cancer Institute2024
Metabolomic signatures of inflammation and metabolic dysregulation in relation to colorectal cancer risk.
Article in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Oncometabolite signatures from tumor-stroma crosstalk as potential non-invasive biomarkers.Cell death discovery · 2026Article
- Metabolomic pattern of ultraprocessed food intake and its association with colorectal cancer risk.Gut · 2025Article
- Physical activity decreases cancer burden by alleviating immunosenescence-related inflammation and improving overall immunity.Cell reports. Medicine · 2025Article
- Development and validation of a plasma-urine metabolism diagnostic model for renal cell carcinoma using machine learning.World journal of urology · 2025Article
- Modified predictive model incorporating the waist-to-hip ratio for advanced colorectal neoplasia: A step toward precision screening.World journal of clinical oncology · 2025Article
- Evolution of the burden of disease for high BMI-associated colorectal cancer, 1990-2021: Global trends, regional heterogeneity, and population risk stratification.Preventive medicine reports · 2025Article
- Years since menopause and its metabolomic signature with biological aging in women at midlife: a population-based study.npj aging · 2025Article
- Revolutionizing gastroenterology and hepatology with artificial intelligence: From precision diagnosis to equitable healthcare through interdisciplinary practice.World journal of gastroenterology · 2025Review
- Multi-omics approach identifies gut microbiota variations associated with depression.NPJ biofilms and microbiomes · 2025Article
- Novel metabolomic predictors of incident colorectal cancer in men and women.Journal of the National Cancer Institute · 2025Article
- Impact of metabolic risk factors on colorectal cancer burden in China: a comprehensive analysis of trends from 1990 to 2021.Frontiers in nutrition · 2025Article
- Global Research Trends and Hotspots in the Role of Cholesterol in Colorectal Cancer: A Bibliometric Analysis.Human mutation · 2025Article
- Systematic investigation of genetically determined plasma and urinary metabolites to discover potential interventional targets for colorectal cancer.Journal of the National Cancer Institute · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 3 countries.
Funding
Abstract
backgroundInflammation and metabolic dysregulation are associated with increased risk of colorectal cancer (CRC); the underlying mechanisms are not fully understood. We characterized metabolomic signatures of inflammation and metabolic dysregulation and evaluated the association of the signatures and individual metabolites with CRC risk.
methodsAmong 684 incident CRC cases and 684 age-matched controls in the Nurses' Health Study (n = 818 women) and Health Professionals Follow-up Study (n = 550 men), we applied reduced rank and elastic net regression to 277 metabolites for markers of inflammation (C-reactive protein, interleukin 6, tumor necrosis factor receptor superfamily member 1B, and growth differentiation factor 15) or metabolic dysregulation (body mass index, waist circumference, C-peptide, and adiponectin) to derive metabolomic signatures. We evaluated the association of the signatures and individual metabolites with CRC using multivariable conditional logistic regression. All statistical tests were 2-sided.
resultsWe derived a signature of 100 metabolites that explained 24% of variation in markers of inflammation and a signature of 73 metabolites that explained 27% of variation in markers of metabolic dysregulation. Among men, both signatures were associated with CRC (odds ratio [OR] = 1.34, 95% confidence interval [CI] = 1.07 to 1.68 per 1-standard deviation increase, inflammation; OR = 1.25, 95% CI = 1.00 to 1.55 metabolic dysregulation); neither signature was associated with CRC in women. A total of 11 metabolites were individually associated with CRC and biomarkers of inflammation or metabolic dysregulation among either men or women.
conclusionWe derived metabolomic signatures and identified individual metabolites associated with inflammation, metabolic dysregulation, and CRC, highlighting several metabolites as promising candidates involved in the inflammatory and metabolic dysregulation pathways for CRC incidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.